Schultz Destiny F, Billadeau Daniel D, Jois Seetharama D
Department of Immunology, Mayo Clinic, Rochester, MN, United States.
Division of Oncology Research, Mayo Clinic, Rochester, MN, United States.
Front Oncol. 2023 Sep 11;13:1258371. doi: 10.3389/fonc.2023.1258371. eCollection 2023.
Spontaneous dimerization of EGF receptors (EGFR) and dysregulation of EGFR signaling has been associated with the development of different cancers. Under normal physiological conditions and to maintain homeostatic cell growth, once EGFR signaling occurs, it needs to be attenuated. Activated EGFRs are rapidly internalized, sorted through early endosomes, and ultimately degraded in lysosomes by a process generally known as receptor down-regulation. Through alterations to EGFR trafficking, tumors develop resistance to current treatment strategies, thus highlighting the necessity for combination treatment strategies that target EGFR trafficking. This review covers EGFR structure, trafficking, and altered surface expression of EGFR receptors in cancer, with a focus on how therapy targeting EGFR trafficking may aid tyrosine kinase inhibitor treatment of cancer.
表皮生长因子受体(EGFR)的自发二聚化以及EGFR信号传导失调与不同癌症的发生发展有关。在正常生理条件下,为维持细胞生长的稳态,一旦EGFR信号传导发生,就需要减弱。活化的EGFR会迅速内化,通过早期内体进行分选,并最终在溶酶体中通过一个通常称为受体下调的过程被降解。通过改变EGFR的运输,肿瘤对当前的治疗策略产生抗性,因此凸显了针对EGFR运输的联合治疗策略的必要性。本综述涵盖了EGFR的结构、运输以及癌症中EGFR受体表面表达的改变,重点关注靶向EGFR运输的疗法如何辅助酪氨酸激酶抑制剂治疗癌症。